NCT00002230已完成3 期
A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected Patients
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 2
研究概览
简要总结
To determine the virologic benefits associated with the addition of hydroxyurea (HU) to combination drug therapy with didanosine (ddI), stavudine (d4T), and efavirenz (DMP) in HIV-infected patients. To assess the safety and tolerance of this regimen, with or without HU.
详细描述
HU or placebo is added 30-60 days after the initiation of DMP, ddI, and d4T combination therapy. Patients are stratified according to antiretroviral experience (naive or experienced). Patients are followed for 48 weeks to determine safety, efficacy, and effect of treatment on viral, immunologic,and biochemical parameters.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Clinical Experience of Thalidomide in Thalassemic PatientsThalassemia, BetaNCT05132270Children's Hospital Karachi135
已完成
1 期
Combination Drug Treatment of Pediatric HIV InfectionHIV InfectionNCT00001818National Cancer Institute (NCI)50
已完成
1 期
The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected PatientsHIV InfectionsNCT00001074National Institute of Allergy and Infectious Diseases (NIAID)140
已完成
2 期
Combination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermediaβ-Thalassemia IntermediaNCT00809042Shiraz University of Medical Sciences120
已完成
2 期
Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major ThalassemiaIron OverloadOxidative StressThalassemia MajorNCT04292314Beni-Suef University350